7. TranS1 (TSON)
Company Profile: TranS1 is a medical-device company that develops products for its proprietary minimally invasive surgical approach to treat degenerative disc disease and instability affecting the spine.Shares of TranS1 surged in early January after the company disclosed that health-care company Humana (HUM) changed its spinal surgery reimbursement policy to include coverage for medically necessary interbody fusion procedures when using TranS1's pre-sacral AxiaLIF approach. In June, TranS1 announced the 10,000th AxiaLIF surgery in the U.S. Current Share Price: $4.51 (Aug. 30) 2011 Total Return: 117% Analyst Ratings: Four research shops follow TranS1, and all four recommend that investors buy shares of the company. The average price target of $6.50 means that analysts still see significant upside to the stock. TheStreet Ratings rates TranS1 a "sell," noting the company's "unimpressive growth in net income, disappointing return on equity and weak operating cash flow."
6. Hansen Medical (HNSN) Company Profile: Hansen Medical develops medical robotics designed for accurate positioning, manipulation and control of catheters and catheter-based technologies. Shares of Hansen Medical jumped to a 52-week high of $5.28 in July, but the rally began in early February after Philips Electronics purchased the rights to develop and market Hansen Medical's Fiber Optic Shape Sensing and Localization, or FOSSL, technology for an upfront payment of $29 million. Hansen Medical is also eligible for $78 million in future payments. Current Share Price: $3.30 (Aug. 30) 2011 Total Return: 121% Analyst Ratings: JPMorgan and Lazard Capital analysts rate Hansen Medical as a "hold" while Piper Jaffray analysts say the stock is a "buy." TheStreet Ratings rates Hansen Medical a "sell," calling special attention to the company's weak operating cash flow.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV